1 SUPPLEMENTAL MATERIALS

2 SUPPLEMENTAL MATERIALS

3 Supplemental Methods:

- 4 Biomarkers
- 5 Samples were batch processed for measurement of high-sensitivity troponin I (hs-troponin;
- 6 ADVIA Centaur® High-Sensitivity Troponin I (TNIH) assay), N-terminal prohormone b-type
- 7 natriuretic protein (NT-pro-BNP; Roche Cobas 6000 Elecsys® proBNP II assay), and high-
- 8 sensitivity c-reactive protein (hsCRP; ADVIA® Chemistry CardioPhaseTM High Sensitivity
- 9 C-Reactive Protein assay). Most participants had antibodies and additional markers measured at
- samples from two earlier time points (<90 days and 90-150 days after infection) including IL-6,
- 11 interleukin 10 (IL-10), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL),
- 12 monocyte chemoattractant protein-1 (MCP-1), interferon gamma (IFN - γ), and tumor necrosis
- 13 factor alpha (TNF-α), and SARS-CoV-2 receptor-binding domain (RBD) immunoglobulin G
- 14 (IgG) (18). These samples were assayed by Monogram Biosciences (South San Francisco, CA)
- using the Quanterix Simoa® platform with Simoa® Assay Kits from Quanterix Corporation
- 16 (Billerica, MA) blinded with respect to patient and clinical information, and assay performance
- 17 was consistent with manufacturers' specifications.
- Hematocrits were collected immediately before CMR with patient sitting right outside the MRIsuite.
- 20 Cardiac MRI imaging sequences:
- 21 The protocol consisted of acquisition of the following sequences after multiplane localizers prior
- to gadolinium injection: fast imaging employing steady state acquisition (FIESTA) cine in the
- 23 axial short axis planes, pre-contrast T1 mapping sequences using the MOLLI 5-(3)-3 technique,
- as well as pre-contrast T2 mapping at the basal, mid, and apical short axis planes and T2 fat-
- saturated weighted black blood spin-echo images in the short axis plane. 8-10 minutes after
- 26 intravenous gadolinium injection, phase sensitive inversion recovery (PSIR) late gadolinium
- enhancement imaging in short axis full stack, 4 chamber full stack, three slices of 2 chamber
- 28 images, and post-contrast T1 mapping sequences were obtained. Inversion times were
- 29 individualized to null the myocardium.
- 30 Arterys software was used for T1 and T2 mapping and ECV calculation using pre- and post-
- 31 contrast MOLLI sequences.
- 32 Cardiopulmonary Exercise Testing
- 33 First, baseline ECG, blood pressure, and rest spirometry including maximum voluntary
- ventilation (MVV) were measured. We determined the work increase per 1 minute step based on
- the expected peak VO₂ from the MVV for a goal 10 minute test, rounded to 5 Watts/min
- increments based on reported exercise (range 10-30W/min) in accordance with guidelines.(58)
- 37 Participants underwent a 2-minute rest phase, 2-minute no resistance warm up, and then 1-
- 38 minute steps. Breath-by-breath oxygen consumption (VO₂) and carbon dioxide production

- 1 (VCO₂) were measured continuously. Participants were blinded to time, wattage, and peak VO₂
- 2 during the test and encouraged to maintain a cadence of ~60 cycles per minute and exercise to
- their maximum ability, with the test stopped prematurely for severe hypertension, relative
- 4 hypotension, moderate to severe angina, ventricular tachycardia or couplets, or ischemic
- 5 changes. Reason for stopping and exertional symptoms were recorded. Exercise effort was
- 6 assessed by Borg Scale and respiratory exchange ratio (RER). Anaerobic threshold was
- 7 determined manually by the exercise physiologist using the slope method.

8 Classification of CPET Limitations

- 9 We considered ventilatory limitation if rest spirometry was abnormal, tidal volume did not
- 10 double over baseline reaching at least 50% of FVC, breathing reserve was <30%, dead space
- 11 ratio (V_D/V_T) was >0.2, or desaturation occurred. We classified participants as having a cardiac
- 12 limitation if there were ischemic ECG changes, the oxygen pulse was reduced and plateaued
- early, AT occurred at less than 40% of predicted maximal VO_2 , and if ventilatory efficiency
- 14 slope (VE/VCO₂) was <32. We considered exercise limitation to be likely due to deconditioning,
- 15 obesity or impaired gas exchange if exercise capacity was reduced without cardiac or ventilatory
- 16 limitation.

1 Supplemental Table 1: Symptom pattern by individual symptoms

	Prior to	Never	Reported at 1st	Reported at 2 nd	Reported at both
	COVID	reported	visit but not 2 nd	visit but not first	visits
	(excluded)		visit	visit	
Any symptom	n/a	15	7	5	33
(including fatigue)					
Chest pain, dyspnea,	n/a	20	9	8	23
or palpitations					
Chest pain	1	41	3	8	7
Dyspnea	1	30	9	3	17
Palpitations	4	32	5	8	11
Fatigue	2	20	7	11	20

2 Supplemental Table 1 Legend: Trajectory of Symptoms by specific symptoms and whether they were present prior

3 to COVID-19, never reported, reported at first visit and resolved prior to second visit, developed after the first visit,

4 or were persistent. Note that those with symptoms prior to COVID are excluded for individual symptoms.

	Symptoms (n=37)	No Symptoms (n=19)	OR (95%CI; p value)
Additional CPET Parameters			
VO ₂ AT, ml/kg/min	10.9 (9.4, 13.1)	13.6 (11.5, 17.4)	0.94 (0.81 to 1.10; p=0.49)
VO ₂ AT % Predicted pVO ₂	56.5 ± 11.2	50.8 ± 10.0	1.05 (0.97-1.13; p=0.21)
Weber Class			p=0.16
A ($pVO_2 > 20$)	22 (61%)	17 (89%)	Ref
$B (pVO_2 16-20)$ C (pVO_2 10-16)	8 (22%)	1(5%) 1(5%)	7.2 (0.6-89) 6 5 (0.41-103)
Rest Respiratory Rate	17.2 ± 4.7	14.6 ± 6.5	1.14 (0.99-1.31; p=0.07)
Tidal Volume at Peak (% FVC)	51.7±9.1	57.1±12.1	0.95 (0.88-1.03; p=0.19)
Dead Space at Peak (% V _T)	17.6±3.7	16.1±2.9	1.27 (0.97-1.68; p=0.08)
Vent. Class ^a I II	23 (72%) 9 (28%)	12 (75%) 4 (25%)	1.55 (0.31-7.72; p=0.59)
Rate Pressure Product, mmHg*bpm	25469± 7023	29712±4088	1.29 per -1000 (1.01 to 1.40; p=0.04)
Rest Echocardiographic Parat	meters		
Left Ventricular Ejection Fraction, %	64.9±5.4	65.3±5.0	0.96 (0.84 to 1.08; p=0.49)
LV Diastolic Function			p=0.08
Indeterminate Mild	6 (17%) 5 (14%)	1 (5%) 1 (5%)	6.9 (0.62-75.8)
LV Strain, %	-20.0±2.6%	-19.7±1.9%	1.01 (0.77 to 1.32; p=0.96)
RV Strain, %	-24.6±5.5%	-23.9±3.3%	0.99 (0.85-1.15; p=0.90)
TAPSE, cm	2.29±0.38	2.28±0.23	1.01 per -10mm (0.85-1.21; p=0.91)
Pulmonary Artery Pressure, mm Hg	24.3±4.6	21.6±2.0	1.36 (1.02 to 1.81; p=0.04)
Pericardial Effusions	3 (8%)	0	n/a
Rest Spirometry			
Forced Vital Capacity, L	3.8±1.0	4.1±0.6	0.82 (0.32-2.07; p=0.67)
Pred Pred	97±17	101±12	0.97 (0.93-1.02; p=0.26)
Forced Expiratory Volume in 1 second, % Pred	102±18	100±12	1.01 (0.97-1.05; p=0.64)
FEV ₁ /FVC, % Pred	104±10	101±5	1.12 (1.01-1.25; p=0.03)
Slow Vital Capacity, % Pred	100±16	104±16	0.99 (0.95-1.03; p=0.55)
Inspiratory Capacity, % Pred	104±27	110±25	0.98 (0.95-1.01; p=0.18)
Maximum Voluntary Ventilation (measured), L/min	130±39	139±28	1.00 (0.98-1.03; p=0.90)

1 Supplemental Table 2. Additional CPET parameters including resting echocardiogram and spirometry

Maximum Voluntary	105+25	104+17	1.00(0.07, 1.02; n=0.06)
Ventilation, % Pred	103±23	104±1/	1.00 (0.97-1.03; p=0.98)

1 Supplemental Table 2 Legend: Echocardiographic parameters by cardiopulmonary symptom status at echo visit

2 (median 6 months). Spirometry was performed at the time of CPET (median 18 months). Odds ratios are adjusted

3 for age, sex, time since SARS-CoV-2 infection, BMI, hospitalization for COVID-19; no change in sensitivity

4 analysis additionally adjusting for medical history. Mild diastolic dysfunction and indeterminate were combined due

5 to small numbers and non-convergence of the model. Abbreviations: AT=Anaerobic threshold; bpm=beats per

minute; FVC=Forced Vital Capacity; HR=heart rate; DBP=diastolic blood pressure; MVV=maximal voluntary
ventilation; SBP=systolic blood pressure; V_D/V_T=Dead space ratio; V_E = minute ventilation; VCO₂=carbon dioxide

8 production; pVO₂=peak oxygen consumption (VO₂); Vent=Ventilatory

		Symptom Present	Symptom Absent	Adjusted Difference
Dyspnea, Chest Pain, Palpitations,	VO ₂ (ml/kg/min)	22.7±8.1	29.6±7.0	-5.2 (-8.3 to -2.1; p=0.001)
or Fatigue at Visit 2 (n=27)	VO ₂ , % predicted	92 ± 22	107 ± 22	-17 (-30 to -4; p=0.01)
Dyspnea, Chest Pain, or	VO ₂ (ml/kg/min)	23.3 ± 8.7	27.0 ± 7.8	-2.8 (-6.2 to 0.6; p=0.10)
Palpitations at Visit 2 (n=30)	VO ₂ , % predicted	95 ± 23	100 ± 23	-6 (-20 to 7, p=0.36)
Self-Reported Reduced Exercise	VO ₂ (ml/kg/min)	24.7 ± 8.6	25.5 ± 8.3	-0.9 (-4.1 to 2.3; p =0.59)
Capacity at Visit 2 (n=31)	VO ₂ , % predicted	94 ± 23	101 ± 23	-7.9 (-20 to 5; p=0.21)
Persistent (n=32) vs Never	VO ₂ (ml/kg/min)	22.7 ± 8.5	29.4 ± 8.4	-5.9 (-9.8 to -2.0; p=0.004)
Symptoms (n=13)	VO ₂ , % predicted	94 ± 23	110 ± 23	-16 (-32 to 0.4; p=0.06)
Symptoms at Visit 1, median 6	VO ₂ (ml/kg/min)	23.0 ± 8.4	27.6 ± 7.9	-2.9 (-6.3 to 0.5; p=0.10)
months (n= 31)	VO ₂ , % predicted	95 ± 23	100 ± 23	-3.3 (-17 to 10; p=0.63)

1	Supplemental Table 3.	Differences in	Peak VO ₂	by Different	Means of	Classifying	Symptoms
---	-----------------------	----------------	----------------------	--------------	----------	-------------	----------

2

3 Supplemental Table 3 Legend: Sensitivity analysis of peak VO₂ (ml/kg/min and % predicted) using different

4 symptom definitions to classify participants. N listed for the number with that symptom finding.

Measure		Value, mean±SD	Adjusted Difference (95%CI; p value)
CPET Peak HR	CI	119±14	-43 (-50 to -36; p<0.001)
During Exercise,	Reduced HR	135±12	-29 (-31 to -24; p<0.001)
bpm	Normal	170±13	
CPET Peak HR,	CI	73±5	-27 (-32 to -21; p<0.001)
%Age Predicted	Reduced HR	84±3	-17 (-20 to -14; p<0.001)
Max	Normal	100±5	
	CI	48±7	-49 (-56 to -42; p<0.001)
CPET AHRR, %	Reduced HR	65±10	-34 (-41 to -27; p<0.001)
	Normal	99±10	
CPET HR	CI	9.1±6.1	-7.9 (-15.3 to -0.4; p=0.04)
Recovery at 1	Reduced HR	10.9±8.3	-4.5 (-11.6 to 2.7; p=0.21)
minute, bpm	Normal	17.1±8.5	
	CI	129±20	-25 (-39 to -11; p=0.002)
Ambulatory Max	Reduced HR	145±19	-4.8 (-17 to 8; p=0.43)
sinus fik, opin	Normal	158±17	
Ambulatory Max	CI	81±12	-10.3 (-19.7 to -0.9; p=0.04)
HR, % Age	Reduced HR	87±14	-2.0 (-13.0 to 9.0; p=0.68)
Predicted Max	Normal	95±7	
	CI	57±22	-31 (-46 to -16; p=0.001)
Ambulatory	Reduced HR	79±25	-6.0 (-20 to 8.1; p=0.38)
AHKK*, %	Normal	90±13	
Ambulatory	CI	57±16	11.5 (2.4 to 20.6; p=0.02)
Minimum HR,	Reduced HR	46±6	1.0 (-4.1 to 6.2; p = 0.68)
bpm	Normal	44±5	
	CI	81±13	7.8 (0.2 to 15.4; p=0.05)
Ambulatory	Reduced HR	76±11	2.5 (-6.4 to 10.9; p=0.59)
Average IIK, Upili	Normal	73±6	
Ambulatory HR	CI	107±37	-62 (-98 to -25; p=0.003)
Variability SDNN	Reduced HR	178±73	0 (-62 to 61; p=0.99)
-	Normal	167±41	

1 Supplemental Table 4: Heart Rate Parameters by Chronotropy and Exercise Capacity

2 Supplemental Table 4 Legend. The first row of each measure is the mean±SD for those with chronotropic

3 incompetence ("CI", $VO_2 < 85\%$, AHRR<80%, and no alternative findings, n=12); the second row is the mean \pm SD

4 for those with a reduced chronotropic response (VO₂ \geq 85% and AHRR<80%, n=13) and the third row is those with

5 peak VO₂ \geq 85% and AHRR \geq 80% (n=23). Those with limited exercise capacity for other reasons were excluded.

6 Adjusted differences are compared to those with normal exercise capacity and heart rate response during exercise.

7 Results were similar whether considering absolute heart rate, percent of age predicted, or adjusted heart rate reserve

8 for both CPET and ambulatory measurements. Ambulatory adjusted heart rate reserve uses (max sinus heart rate -

9 average heart rate)/(220-age-average heart rate). Abbreviations: HR=heart rate, bpm=beats per minute,

10 CI=chronotropic incompetence, AHRR=adjusted heart rate reserve, SDNN=standard deviation n-to-n.



1 Supplemental Figure 1. Cardiac Rhythms During Button Pushes (n=38)

2

Supplemental Figure 1 Legend: Individual participant analysis of number of button pushes and assocaited rhythm with each participant on the x axis and the number of times that individual pushed the symptom button on the y axis with each identified rhythm coded by color. Most button pushes were associated with sinus rhythm or sinus tachycardia, with supraventricular ectopy (premature atrial contractions) present among a few individuals especially the 3 with the most button pushes.